Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
816.10
+8.43 (1.04%)
At close: Oct 27, 2026, 4:00 PM EDT
815.75
-0.35 (-0.04%)
Pre-market: Oct 28, 2026, 5:26 AM EDT
Regeneron Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 28 analysts polled by S&P Global, Regeneron Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $867.33. The average 1-year stock price forecast is 6.28% higher than the current stock price, while the lowest is $730 (-10.55%) and the highest is $1,030 (+26.21%).
Price Target: $867.33 (+6.28%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 16 | 16 | 14 | 14 | 13 | 15 |
| Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Hold | 8 | 8 | 10 | 9 | 9 | 8 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 29 | 28 | 28 | 27 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Buy Maintains $960 → $980 | Buy | Maintains | $960 → $980 | +20.08% | Oct 21, 2026 |
| Leerink Partners | Leerink Partners | Hold Maintains $824 → $835 | Hold | Maintains | $824 → $835 | +2.32% | Oct 20, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $854 → $865 | Buy | Maintains | $854 → $865 | +5.99% | Oct 19, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $750 | Hold | Maintains | $750 | -8.10% | Oct 15, 2026 |
| UBS | UBS | Buy Initiates $660 → $978 | Buy | Initiates | $660 → $978 | +19.84% | Oct 14, 2026 |
Financial Forecast
Revenue This Year
17.60B
from 14.34B
Increased by 22.71%
Revenue Next Year
18.59B
from 17.60B
Increased by 5.64%
EPS This Year
58.85
from 44.31
Increased by 32.81%
EPS Next Year
62.70
from 58.85
Increased by 6.55%
EPS and Forward PE are based on non-GAAP adjusted numbers.